Clinical Trials

Sensorion secures approval to start SENS-401 phase 2 trial in sudden sensorineural hearing loss

The Heads of Medicines Agencies (HMA), a European network of the heads of the national competent authorities, has approved Sensorion's volunturary harmonization procedure (VHP) application to initiate a phase 2 trial for SENS-401 for the treatment of sudden sensorineural hearing loss (SSNHL) in adults.

AC Immune reports clinical milestones for ACI-24 vaccine in Alzheimer’s disease and Down Syndrome

Swiss clinical-stage biopharmaceutical firm AC Immune has announced two clinical milestone events related to ACI-24, its anti-Abeta vaccine against Alzheimer's disease and Abeta-related cognitive decline in Down Syndrome.

Immunocore initiates phase 1 study of IMCnyeso in patients with solid tumors

Immunocore, a T Cell Receptor (TCR) biotechnology company, said that it has dosed the first patient in a phase I study of IMCnyeso, an ImmTAC molecule, as part of a collaboration with GlaxoSmithKline (GSK).

Teva, Regeneron’s fasinumab succeeds in phase 3 osteoarthritis trial

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals reported positive topline results for fasinumab from a phase 3 trial in patients with chronic pain from osteoarthritis (OA) of the knee or hip.

Novocure, US Oncology collaborate on advanced pancreatic cancer trial

Novocure and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer.

Inovio doses first patient in HIV vaccine trial

Inovio Pharmaceuticals has dosed the first participant with PENNVAX-GP in a randomized clinical trial that will assess its ability to drive remission of HIV infection.

Izana begins phase II proof-of-concept study of spinal arthritis drug

UK-based biopharmaceutical company Izana Bioscience has commenced a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis.

Samsung Bioepis to start phase 1 trial of pancreatitis drug SB26

Samsung Bioepis said that it will soon start a phase 1 study to evaluate its pancreatitis drug SB26 in healthy volunteers.

Spark Therapeutics reports mixed results from hemophilia gene therapy trial

Spark Therapeutics’ SPK-8011, an investigational gene therapy treatment for hemophilia A, was successful in reducing bleeding in a phase 1/2 trial, but also resulted in one of the participants getting hospitalized.